# Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

> **NCT02228213** · PHASE2 · COMPLETED · sponsor: **Innate Immunotherapeutics** · enrollment: 93 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** MIS416
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT02228213
- **Lead sponsor:** Innate Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-05
- **Final completion:** 2017-06
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2017-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228213, "Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02228213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*